Back Hepatitis C

Hepatitis C

FDA Approves Simeprevir (Olysio) for Chronic Hepatitis C

The U.S. Food and Drug Administration last Friday approved Janssen/Medivir's next-generation hepatitis C virus (HCV) protease inhibitor simeprevir -- to be marketed under the brand name Olysio -- as an add-on to interferon-based therapy for the treatment of people with genotype 1 chronic hepatitis C. It is not yet approved for use in interferon-free combinations.

alt

AASLD 2013: Aspirin and Cenicriviroc May Help Reduce Liver Fibrosis

Hepatitis C patients who took low-dose aspirin after liver transplantation experienced slower fibrosis progression, researchers reported at the AASLD Liver Meeting this month in Washington, DC. Two other studies showed that cenicriviroc -- a drug being developed for HIV treatment that blocks both CCR5 and CCR2 cell surface receptors -- had anti-inflammatory and anti-fibrotic activity in mice and rats.

alt

AASLD 2013: Black Hepatitis C Patients Do Well on Sofosbuvir Oral Regimens

Interferon-free treatment using a single daily combination pill containing sofosbuvir plus ledipasvir demonstrated potent anti-HCV activity and was generally well-tolerated in a primarily African-American inner city population with genotype 1a hepatitis C, researchers reported at the recent AASLD Liver Meeting in Washington, DC. Adding a third drug resulted in high early post-treatment response rates with shorter treatment.

alt

AASLD 2013: Liver Meeting Ends with Hepatitis C Debrief and the Future of Treatment

The final day of AASLD Liver Meeting, recently held in Washington, DC, featured an overview of the status of new hepatitis C therapies, similarities between HCV and HIV, and a look towards the future of hepatitis C treatment. The development of next-generation HCV drugs has been remarkably rapid and experts agree that it may soon be possible to cure all patients with hepatitis C, but access is likely to be a challenge.

alt

AASLD 2013: Hepatitis C Treatment Reduces Liver Cancer and Death, But Most Remain Untreated

Hepatitis C treatment that leads to viral suppression significantly reduces the likelihood of liver disease progression and liver-related mortality, but most patients remain untreated, according to a presentation at the 64th AASLD Liver Meeting last week in Washington, DC. Other studies found that a growing proportion of liver transplants are due to hepatocellular carcinoma, which can still occur even after treatment.

alt

AASLD 2013: Faldaprevir All-oral Regimen Shows 100% Early Sustained Response for HCV 1a

An interferon-free regimen of faldaprevir, deleobuvir, and PPI-668 led to 4-week post-treatment sustained virological response (SVR4) in all treatment-naive patients with hard-to-treat HCV subtype 1a in an ongoing Phase 2 trial, according to a late-breaking poster presentation at the 64th AASLD Liver Meeting this month in Washington, DC.

alt

AASLD 2013: Fixed-dose Sofosbuvir/Ledipasvir Cures Most Genotype 1 Hepatitis C

At least 95% of newly treated genotype 1 hepatitis C patients and prior non-responders achieved sustained virological response using a fixed-dose combination of sofosbuvir plus ledipasvir, with or without ribavirin, according to findings from the LONESTAR study presented the 64th AASLD Liver Meeting last week in Washington, DC. While response rates were high overall, the 2 relapsers in the trial were not taking ribavirin.

alt

AbbVie All-Oral Regimen Produces 96% Cure Rate, Effective Against Both HCV 1a and 1b

A 12-week interferon-free quadruple regimen of 3 direct-acting antiviral agents plus ribavirin led to sustained virological response in 95% of previously untreated, non-cirrhotic hepatitis C patients with harder-to-treat HCV subtype 1a and 98% of those with subtype 1b, AbbVie announced this week.

alt

AASLD 2013: Sofosbuvir + Ribavirin for 12 or 24 Weeks Cures Most Genotype 2-3 Hepatitis C Patients

A dual oral regimen of sofosbuvir plus ribavirin led to sustained response for 93% of genotype 2 hepatitis C patients treated for 12 weeks and 85% of genotype 3 patients treated for 24 weeks, researchers reported last week at the 64th AASLD Liver Meeting in Washington, DC. A related study found that adding ribavirin to this combination may be an option for harder-to-treat individuals.

alt